肝腎症候群治療市場：タイプ、治療法、エンドユーザー別-2025-2030年の世界予測

肝腎症候群治療市場は、2023年に45億6,000万米ドルと評価され、2024年には48億米ドルに達すると予測され、CAGR 5.47％で成長し、2030年には66億2,000万米ドルに達すると予測されています。

肝腎症候群（HRS）治療は、進行した肝疾患患者における腎臓の急速な悪化を特徴とする複雑な病態の管理に重点を置いています。血管収縮剤やアルブミンなどの薬物療法、透析療法、肝移植、新たな生物製剤などが含まれます。HRS治療の必要性は、この病態が高い罹患率と死亡率を伴うためであり、患者の転帰を改善するためには早期かつ効果的な介入が不可欠です。HRS治療の適用範囲は病院、診療所、研究機関にわたり、主に肝硬変や肝移植を待つ患者を対象としています。HRS治療市場に関する洞察は、世界の肝疾患の増加、治療法の進歩、移植を受ける患者の増加に後押しされた大幅な成長を強調しています。しかし、治療費の高騰、移植臓器の入手可能性の制限、新規治療法の承認プロセスを阻害する規制上の課題などの限界に直面しています。ビジネスチャンスという点では、新規バイオマーカーと標的治療ソリューションを提供する治療法の市場開拓が有望です。製薬企業と研究機関の共同研究は、創薬を加速し、治療戦略を強化することができます。研究開発への投資と適応性の高い臨床試験デザインは、個別化された治療計画の開発につながり、患者固有の転帰を改善する可能性もあります。市場関係者は、アンメットニーズを考慮すれば、有望な道筋を示す生物製剤と再生医療のイノベーションに注力することが推奨されます。課題は、厳しい規制状況を乗り切ることと、治療費の手頃さに対処することであり、これには戦略的な価格設定と、広く利用しやすくするための医療政策の強化が必要です。新興国市場の多面的な性質を認識した上で、企業はデジタルヘルス企業との提携を模索し、より良い疾病管理と患者の治療レジメンへのアドヒアランスを可能にするプラットフォームを開発し、データを活用して健康アウトカムを改善する必要があります。

市場力学：急速に進化する肝腎症候群治療市場の主要市場インサイトを公開

肝腎症候群治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 肝腎症候群の有病率の上昇
  • ファスト・トラックおよびオーファンドラッグ指定の増加
  • 疾患認知度の向上と患者支援プログラムの増加
• 市場抑制要因
  • 高い治療費、製品回収事故
• 市場機会
  • 先端技術を取り入れた研究開発の増加
  • 革新的なHRS治療に注力するバイオベンチャー企業への資金援助とベンチャーキャピタルの増加
• 市場の課題
  • 薬物使用に関連する副作用とリスク

ポーターの5つの力：肝腎症候群治療市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：肝腎症候群治療市場における外部からの影響の把握

外部マクロ環境要因は、肝腎症候群治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析肝腎症候群治療市場における競合情勢の把握

肝腎症候群治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス肝腎症候群治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、肝腎症候群治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨肝腎症候群治療市場における成功への道筋を描く

肝腎症候群治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 肝腎症候群の罹患率の上昇
    • ファストトラック指定と希少疾病用医薬品指定の増加
    • 病気の認知度と患者支援プログラムの拡大
  • 抑制要因
    • 高額な治療費と製品リコール事件
  • 機会
    • 先進技術を取り入れるための研究開発の強化
    • 革新的なHRS治療に焦点を当てたバイオテクノロジー新興企業への資金とベンチャーキャピタルの増加
  • 課題
    • 薬物使用に関連する副作用とリスク
• 市場セグメンテーション分析
  • 治療：外科的介入の有効性と治療結果を改善するための継続的な革新
  • エンドユーザー：病院や診療所における包括的なヘルスケアソリューションとサービスの利用可能性
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 肝腎症候群治療市場：タイプ別

• 1型肝腎症候群
• 2型肝腎症候群

第7章 肝腎症候群治療市場治療別

• 外科的治療
  • 肝臓移植
  • 腎代替療法
  • 外科的シャント術
• 治療薬
  • グリプレシン
  • ルーカシン
  • テルリヴァズ

第8章 肝腎症候群治療市場：エンドユーザー別

• 学術調査機関
• 外来手術センター
• 病院・クリニック

第9章 南北アメリカの肝腎症候群治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の肝腎症候群治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの肝腎症候群治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • マリンクロット社、SCCM 2023会議で肝腎症候群の改善を目的としたTERLIVAZに関する重要な研究結果を発表
  • FDA、肝腎症候群の急速な腎不全に対する初の治療を承認
• 戦略分析と提言

企業一覧

• Aetna Inc.
• Baxter International Inc
• Becton, Dickinson and Company
• Biocon Limited
• BioVie Inc
• Cadila Healthcare Limited
• Cumberland Pharmaceuticals Inc
• Edwards Lifesciences Corporation
• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc
• Mallinckrodt Inc
• Medtronic plc
• Neovii Pharmaceuticals AG
• Novartis International AG
• Orphan Therapeutics, LLC
• PharmaIN Corporation
• Samarth Life Sciences Pvt Ltd.
• Swastik Life Sciences
• United Biotech Pvt Ltd.

LIST OF FIGURES

• FIGURE 1. HEPATORENAL SYNDROME TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. HEPATORENAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. HEPATORENAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HEPATORENAL SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HEPATORENAL SYNDROME TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE 1 HEPATORENAL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE 2 HEPATORENAL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY RENAL REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL SHUNTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GLYPRESSIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY LUCASSIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TERLIVAZ, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 43. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 44. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 45. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 70. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 71. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 72. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 75. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 76. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 77. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 129. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 150. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 155. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 159. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 160. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 161. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 162. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 163. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 165. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 169. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 170. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 175. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 179. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 180. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 181. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 182. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 183. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 184. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 185. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 186. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 187. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 188. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 190. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 195. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 204. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 205. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 209. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 210. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 214. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 215. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 219. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 220. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 224. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 229. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 230. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 234. HEPATORENAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 235. HEPATORENAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Hepatorenal Syndrome Treatment Market was valued at USD 4.56 billion in 2023, expected to reach USD 4.80 billion in 2024, and is projected to grow at a CAGR of 5.47%, to USD 6.62 billion by 2030.

Hepatorenal syndrome (HRS) treatment is focused on managing a complex condition characterized by rapid kidney deterioration in individuals with advanced liver disease. The scope includes pharmaceutical therapies such as vasoconstrictors and albumin, dialysis modalities, liver transplants, and emerging biologics. The necessity of HRS treatment arises due to the condition's association with high morbidity and mortality rates, making early and effective intervention critical in improving patient outcomes. Its application spans across hospital settings, clinics, and research institutions, primarily targeting patients with conditions like cirrhosis and those awaiting liver transplants. Insights into the HRS treatment market highlight substantial growth propelled by an increase in liver diseases globally, advancements in therapeutic methods, and a growing transplant recipient population. However, the market faces limitations, such as the high cost of treatment, limited availability of transplant organs, and regulatory challenges that hinder approval processes for new therapies. In terms of opportunity, the market holds potential in the development of novel biomarkers and therapies that offer targeted treatment solutions. Collaborations between pharmaceutical companies and research organizations can accelerate drug discovery and enhance therapeutic strategies. Investment in R&D and adaptive clinical trial designs could also lead to the development of personalized treatment plans, improving patient-specific outcomes. Market players are recommended to focus on innovation in biologics and regenerative medicines, which present promising avenues given the unmet clinical needs. Challenges lay in navigating the stringent regulatory landscapes and addressing the affordability of treatments, which require strategic pricing and enhanced healthcare policies to facilitate widespread accessibility. Recognizing the multidimensional nature of the market, businesses should also explore partnerships with digital health companies to develop platforms that allow for better disease management and patient adherence to therapy regimens, leveraging data for improved health outcomes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hepatorenal Syndrome Treatment Market

The Hepatorenal Syndrome Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of hepatorenal syndrome
  • Increasing fast track and orphan drug designations
  • Growing disease awareness & patient support programs
• Market Restraints
  • High treatment costs, and product recall incidents
• Market Opportunities
  • Increasing research & development to incorporate advanced technologies
  • Increased funding and venture capital for biotech start-ups focusing on innovative HRS treatments
• Market Challenges
  • Side-effects and risks related to drug usage

Porter's Five Forces: A Strategic Tool for Navigating the Hepatorenal Syndrome Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hepatorenal Syndrome Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hepatorenal Syndrome Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hepatorenal Syndrome Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hepatorenal Syndrome Treatment Market

A detailed market share analysis in the Hepatorenal Syndrome Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hepatorenal Syndrome Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hepatorenal Syndrome Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hepatorenal Syndrome Treatment Market

A strategic analysis of the Hepatorenal Syndrome Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hepatorenal Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include Aetna Inc., Baxter International Inc, Becton, Dickinson and Company, Biocon Limited, BioVie Inc, Cadila Healthcare Limited, Cumberland Pharmaceuticals Inc, Edwards Lifesciences Corporation, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Mallinckrodt Inc, Medtronic plc, Neovii Pharmaceuticals AG, Novartis International AG, Orphan Therapeutics, LLC, PharmaIN Corporation, Samarth Life Sciences Pvt Ltd., Swastik Life Sciences, and United Biotech Pvt Ltd..

Market Segmentation & Coverage

This research report categorizes the Hepatorenal Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Type 1 Hepatorenal Syndrome and Type 2 Hepatorenal Syndrome.
• Based on Treatment, market is studied across Surgical Treatment and Therapeutics. The Surgical Treatment is further studied across Liver Transplantation, Renal Replacement Therapy, and Surgical Shunting. The Therapeutics is further studied across Glypressin, Lucassin, and Terlivaz.
• Based on End-User, market is studied across Academic & Research Institutes, Ambulatory Surgical Centers, and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of hepatorenal syndrome
    • 5.1.1.2. Increasing fast track and orphan drug designations
    • 5.1.1.3. Growing disease awareness & patient support programs
  • 5.1.2. Restraints
    • 5.1.2.1. High treatment costs, and product recall incidents
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing research & development to incorporate advanced technologies
    • 5.1.3.2. Increased funding and venture capital for biotech start-ups focusing on innovative HRS treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Side-effects and risks related to drug usage
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment: Ongoing innovations to improve the efficacy and treatment outcomes of surgical interventions
  • 5.2.2. End-User: Availability of comprehensive healthcare solutions and services in hospitals and clinics
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Hepatorenal Syndrome Treatment Market, by Type

• 6.1. Introduction
• 6.2. Type 1 Hepatorenal Syndrome
• 6.3. Type 2 Hepatorenal Syndrome

7. Hepatorenal Syndrome Treatment Market, by Treatment

• 7.1. Introduction
• 7.2. Surgical Treatment
  • 7.2.1. Liver Transplantation
  • 7.2.2. Renal Replacement Therapy
  • 7.2.3. Surgical Shunting
• 7.3. Therapeutics
  • 7.3.1. Glypressin
  • 7.3.2. Lucassin
  • 7.3.3. Terlivaz

8. Hepatorenal Syndrome Treatment Market, by End-User

• 8.1. Introduction
• 8.2. Academic & Research Institutes
• 8.3. Ambulatory Surgical Centers
• 8.4. Hospitals & Clinics

9. Americas Hepatorenal Syndrome Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Hepatorenal Syndrome Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Hepatorenal Syndrome Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Mallinckrodt Announces Key Study Results on TERLIVAZ for Hepatorenal Syndrome Reversal at SCCM 2023 Congress
  • 12.3.2. FDA Approves First-Ever Treatment for Rapid Kidney Failures in Hepatorenal Syndrome
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Aetna Inc.
• 2. Baxter International Inc
• 3. Becton, Dickinson and Company
• 4. Biocon Limited
• 5. BioVie Inc
• 6. Cadila Healthcare Limited
• 7. Cumberland Pharmaceuticals Inc
• 8. Edwards Lifesciences Corporation
• 9. F. Hoffmann-La Roche AG
• 10. GlaxoSmithKline plc
• 11. Mallinckrodt Inc
• 12. Medtronic plc
• 13. Neovii Pharmaceuticals AG
• 14. Novartis International AG
• 15. Orphan Therapeutics, LLC
• 16. PharmaIN Corporation
• 17. Samarth Life Sciences Pvt Ltd.
• 18. Swastik Life Sciences
• 19. United Biotech Pvt Ltd.